- AZ505
-
- $58.00
-
2026-07-14
- CAS:1035227-43-0
- Purity: 98.48%
- Supply Ability: 10g
|
| Product Name: | AZ505 | | Synonyms: | N-Cyclohexyl-N3-[2-(3,4-dichlorophenyl)ethyl]-N-(2-{[2-(5-hydroxy-3-oxo-3,4-dihydro-2H-1,4-benzoxazin-8-yl)ethyl]amino}ethyl)-alaninamide;N-Cyclohexyl-3-(3,4-dichlorophenethylamino)-N-[2-[[2-[5-hydroxy-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-8-yl]ethyl]amino]ethyl]propanamide;AZ-505;AZ 505;CS-2253;Propanamide, N-cyclohexyl-3-[[2-(3,4-dichlorophenyl)ethyl]amino]-N-[2-[[2-(3,4-dihydro-5-hydroxy-3-oxo-2H-1,4-benzoxazin-8-yl)ethyl]amino]ethyl]-;AZ505 free base;Histone Methyltransferase,AZ 505,inhibit,AZ505,Inhibitor,AZ-505;AZ505, 10 mM in DMSO | | CAS: | 1035227-43-0 | | MF: | C29H38Cl2N4O4 | | MW: | 577.54 | | EINECS: | | | Product Categories: | | | Mol File: | 1035227-43-0.mol |  |
| | AZ505 Chemical Properties |
| Boiling point | 782.5±60.0 °C(Predicted) | | density | 1.32±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | Soluble in DMSO | | form | crystalline solid | | pka | 8.59±0.20(Predicted) | | color | Off-white to light brown | | InChIKey | LIBVHXXKHSODII-UHFFFAOYSA-N | | SMILES | O=C1NC(C(O)=CC=C2CCNCCN(C3CCCCC3)C(CCNCCC4=CC(Cl)=C(Cl)C=C4)=O)=C2OC1 |
| WGK Germany | WGK 3 | | Storage Class | 11 - Combustible Solids |
| | AZ505 Usage And Synthesis |
| Uses | AZ505 is a potent inhibitor of SMYD2, which plays an important role in epigenetic signalling. Inhibiition of SMYD2 also functions as an activator of the tumor suppressor proteins. | | Biological Activity | Potent and selective SMYD2 inhibitor in vitro and in vivo.
AZ505 is a potent and selective SET and MYND domain-containing protein SMYD2 inhibitor (IC50 = 120 nM) th at targets the substrate-binding site in a peptide substrate-competitive and cofactor SAM-uncompetitive manner, exhibiting no activity against lysine methyltransferases (KMTs) SMYD3, DOT1L, EZH2, GLP, G9A and SET7/9 (IC50 >83.3 μM). AZ505 downregulates p53 K370 monomethylation in U2OS cells (10h 10 μM) and delays cyst growth in early- (5 mg/kg/day i.p. from P7-P27) as well as later-stage (10 mg/kg via i.p. 3x per wk from P42-3.5 months, then 1x per wk from 3.5–6 months) Pkd1 conditional knockout mouse models in vivo. | | IC 50 | SMYD2 |
| | AZ505 Preparation Products And Raw materials |
|